Table 3.
SPM risks at various anatomical sites based on previous surgery and chemotherapy treatments in colorectal CA patients.
| Events | Treatment for colorectal cancer | P | |||||
|---|---|---|---|---|---|---|---|
| Surgery only | Surgery combined with chemotherapy | ||||||
| Obs | SIR | 95% CI | Obs | SIR | 95% CI | ||
| All sites | 15,449 | 1.15* | 1.13–1.17 | 5,561 | 1.17* | 1.14–1.2 | 0.445 |
| All sites excluding non-melanoma skin | 15,364 | 1.15* | 1.13–1.17 | 5,530 | 1.17* | 1.14–1.2 | 0.463 |
| All solid tumors | 14,000 | 1.18* | 1.16–1.2 | 5,116 | 1.21* | 1.18–1.24 | 0.286 |
| Oral cavity and pharynx | 357 | 1.17* | 1.05–1.29 | 93 | 0.83 | 0.67–1.01 | 0.031# |
| Esophagus | 196 | 1.26* | 1.09–1.45 | 53 | 1 | 0.75–1.3 | 0.29 |
| Stomach | 330 | 1.36* | 1.22–1.52 | 98 | 1.19 | 0.97–1.45 | 0.444 |
| Small intestine | 190 | 2.91* | 2.51–3.36 | 131 | 5.62* | 4.7–6.67 | 0.011# |
| Colon and rectum | 2,760 | 2.07* | 1.99–2.15 | 1116 | 2.45* | 2.31–2.6 | 0.009# |
| Liver | 229 | 1.05 | 0.92–1.2 | 68 | 0.84 | 0.65–1.07 | 0.237 |
| Gallbladder | 34 | 0.89 | 0.62–1.25 | 9 | 0.7 | 0.32–1.33 | 0.621 |
| Pancreas | 466 | 1.09 | 1–1.2 | 159 | 1.11 | 0.95–1.3 | 0.894 |
| Larynx | 110 | 1.01 | 0.83–1.22 | 44 | 1.13 | 0.82–1.51 | 0.68 |
| Lung and bronchus | 2,410 | 1.13* | 1.08–1.17 | 770 | 1.06 | 0.99–1.14 | 0.319 |
| Bones and joints | 6 | 0.51 | 0.19–1.1 | 9 | 2.07 | 0.94–3.92 | 0.059 |
| Soft tissue including heart | 81 | 1.08 | 0.86–1.35 | 26 | 0.99 | 0.65–1.45 | 0.781 |
| Melanoma of the skin | 528 | 0.90* | 0.82–0.98 | 178 | 0.87 | 0.75–1.01 | 0.809 |
| Breast | 1,364 | 0.99 | 0.93–1.04 | 500 | 0.90* | 0.82–0.98 | 0.185 |
| Cervix uteri | 42 | 1 | 0.72–1.35 | 20 | 1.03 | 0.63–1.6 | 0.93 |
| Corpus uteri | 361 | 1.31* | 1.18–1.45 | 183 | 1.58* | 1.36–1.82 | 0.193 |
| Uterus, NOS | 9 | 0.96 | 0.44–1.82 | 6 | 1.71 | 0.63–3.72 | 0.474 |
| Ovary | 96 | 0.69* | 0.56–0.84 | 48 | 0.89 | 0.66–1.18 | 0.28 |
| Vagina | 7 | 0.71 | 0.29–1.47 | 6 | 1.66 | 0.61–3.62 | 0.299 |
| Prostate | 2,301 | 0.97 | 0.93–1.01 | 808 | 0.96 | 0.9–1.03 | 0.849 |
| Urinary bladder | 861 | 1.06 | 0.99–1.13 | 278 | 1.08 | 0.96–1.22 | 0.83 |
| Kidney | 443 | 1.08 | 0.98–1.19 | 175 | 1.17* | 1–1.36 | 0.553 |
| Renal pelvis | 35 | 0.99 | 0.69–1.38 | 13 | 1.16 | 0.62–1.99 | 0.735 |
| Ureter | 22 | 0.97 | 0.61–1.47 | 13 | 1.84 | 0.98–3.14 | 0.243 |
| Eye and orbit | 11 | 0.54* | 0.27–0.97 | 3 | 0.42 | 0.09–1.22 | 0.733 |
| Brain and other nervous system | 119 | 0.9 | 0.75–1.08 | 41 | 0.86 | 0.61–1.16 | 0.836 |
| Thyroid | 235 | 1.52* | 1.33–1.73 | 134 | 1.96* | 1.64–2.32 | 0.158 |
| Lymphoma | 506 | 0.83* | 0.76–0.9 | 187 | 0.89 | 0.77–1.03 | 0.544 |
| Myeloma | 222 | 1 | 0.87–1.14 | 47 | 0.62* | 0.45–0.82 | 0.019# |
| Leukemia | 376 | 0.97 | 0.87–1.07 | 110 | 0.85 | 0.7–1.03 | 0.392 |
CA, classical adenocarcinoma; Obs, observed events; SIR, standard incidence ratio; CI, confidence interval;
*
P < 0.05 (compared with general population).
#
P < 0.05. P-values comparing SIRs for colorectal CA survivors who received surgery only vs. surgery combined with chemotherapy were calculated using Poisson regression.